In the department of Hematology/Oncology we treat children with cancer (including leukemia), non-malignant hematological disorders, chronic active EB virus infection, and immune dysfunctions. With the progress of multimodal treatment (combination of anti-cancer drugs, surgery, radiation therapy, etc.), the survival rate is now around 70%.
While the patients with childhood cancer have becomes curable, late complications (sequelae) due to the severe treatment are becoming a new challenge for those who have experienced childhood cancer. In Pediatric Cancer Center, a multidisciplinary team is active for supporting children with cancer and their family, sustaining their daily lives including school activity, managing late complications, and improving the treatment further.
We have developed new treatment modalities for better survival of children with difficult diseases. Under the slogan of "cure without late complications," we have successfully minimized treatment-related late complications with reduced intensity conditioning (RIC) for hematopoietic stem cell transplantation and immunotherapy, which have smaller side effects. We are also focusing on long-term follow-up for children who have experienced cancer. In addition, we are also welcome to the second opinion.
• Childhood cancer
Leukemia, malignant lymphoma, neuroblastoma, brain tumor, hepatoblastoma, rhabdomyosarcoma, nephroblastoma, etc.
• Other hematological disorders
Aplastic anemia, myelodysplastic syndrome (MDS), etc.
• Epstein-Barr virus (EBV)-related diseases
Chronic active EBV infection, hemophagocytic lymphohistiocytosis, etc.
Primary immunodeficiency, other immune dysfunctions, infants positive for expanded new born screening for severe combined immunodeficiency (SCID), etc.
We perform all types of hematopoietic stem cell transplantation (HSCT) including bone marrow transplantation, peripheral blood stem cell transplantation, and umbilical cord blood transplantation. Our team has been certified as an unrelated hematopoietic stem cell transplantation facility. We are leading pediatric HSCT in Japan (based on the Report of Japan Hematopoietic Cell Transplantation Data Center National Survey).
In addition, we perform HLA-haploidentical HSCT, including HCT with post-transplant cyclophosphamide (PTCY) for non/less-malignant hematological diseases, and T-cell replete HSCT for advanced leukemia.
The total number of new patients with childhood cancer was 49 in 2020. The total number of HSCT was 30 in 2020.
We performed 9 autologous HSCT and 21 allogeneic HSCT. We generally use RIC for conditioning HSCT. Of the 21 allogeneic HSCT in 2020, 20 were transplanted using RIC. The number of T-cell replete HLA-haploidentical HSCT for advanced cases was 6. The total number of autologous and allogeneic HSCT was 1043 between 1991 and the end of 2020.